Lexicon and MannKind Q3 ’18 Earnings Updates
Lexicon and MannKind hosted their Q3 ’18 earnings calls and provided updates for their respective marketed and pipeline products. Lexicon continues to state they are preparing for an early 2019 FDA adcom for Zynquista (sotagliflozin) T1DM indication. Recall, the PDUFA is March 22, 2019. Below are highlights from the respective earnings calls.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.